[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552716":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":40,"locations":47,"responsibleParty":75,"collaborators":77,"id":81,"slug":26,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":26,"enrollmentInfo":90,"targetDuration":26,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":105,"whyStopped":26,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Centre Paul Strauss","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hypofractionated radiotherapy + Liposomal Transcorcetin (L-TC)","EXPERIMENTAL","L-TC as an IV infusion over 90 minutes at a fixed dose of 300 mg daily before each HFRT fraction, for a total of 5 days corresponding to the planned five daily HFRT fractions. The intravenous infusion should begin 2 hours before each HFRT fraction. Radiotherapy is scheduled to coincide with the plasma peak, which occurs approximately 2 hours after the start of the infusion. + HFRT treatment will be administered in control group as 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.",[13],"Drug: Administration of L-TC",{"label":15,"type":16,"description":17,"interventionNames":18},"Hypofractionated radiotherapy alone","ACTIVE_COMPARATOR","HFRT treatment will be administered in control group as 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.",[19],"Radiation: HFRT alone",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Administration of L-TC","Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"RADIATION","HFRT alone","HFRT : 30 Gy in 5 fractions of 6 Gy.\n\n1 fraction per day, 5 days per week.",[15],[33,37],{"name":34,"affiliation":35,"role":36},"Isabelle CHAMBRELANT, MD","Institut de cancérologie Strasbourg Europe","PRINCIPAL_INVESTIGATOR",{"name":38,"affiliation":35,"role":39},"Georges NOEL, MD, PhD","STUDY_CHAIR",[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Manon VOEGELIN","CONTACT","368339523","+33","promotion-rc@icans.eu",[48,63],{"facility":49,"status":26,"city":50,"state":26,"zip":26,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"CGFL","Dijon","France",{"type":53,"coordinates":54},"Point",[55,56],5.01391,47.31344,{"lat":56,"lon":55},[59],{"name":60,"role":43,"phone":61,"phoneExt":26,"email":62},"Gilles TRUC","33380737518","gtruc@cgfl.fr",{"facility":64,"status":26,"city":65,"state":26,"zip":26,"country":51,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"ICANS","Strasbourg",{"type":53,"coordinates":67},[68,69],7.74553,48.58392,{"lat":69,"lon":68},[72],{"name":73,"role":43,"phone":74,"phoneExt":26,"email":46},"Georges NOEL","33368339523",{"type":76,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[78],{"name":79,"class":80},"LEAF4Life, Inc.","INDUSTRY","100552716",false,"NCT06476704","Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","Phase 2 Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","PRACTISS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Localized or locally advanced soft tissue sarcoma of extremity proven by biopsy histological grade 2 and 3.\n* Pathological expert proof-reading in reference centers\n* HFRT and surgery planned (regardless the potential inclusion in this trial) as decided in a multidisciplinary tumor board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021)\n* R0 surgery is feasible, in reference centers\n* Pre-biopsy MRI available\n* Performance status of 0-2 and life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Patient who cannot undergo MRI\n* Patients with localized or locally advanced soft tissue sarcoma of extremity proven by biopsy with histological grade 1\n* Previous radiation in the area\n* Woman who is pregnant or breastfeeding\n* Soft tissue sarcoma developed in irradiated area.\n* Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans\n* Patient with metastatic disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.","ALL","18 Years",{"count":91,"type":92},42,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","This is phase II randomized, multicenter study of treatment with L-TC and preoperative HFRT in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.\n\nEligible patients will be randomly assigned 2:1 to receive a preoperative HFRT alone (Arm A) or L-TC with preoperative HFRT (Arm B).",[98],"Sarcoma",[100,101,102,103,104],"hypofractionated radiotherapy","soft tissue sarcoma","hypoxia","liposomal transcrocetin","neo-adjuvant","NOT_YET_RECRUITING","2026-06-03",{"date":108,"type":109},"2026-06-04","ACTUAL",{"date":111,"type":92},"2026-07-01",{"date":113,"type":92},"2033-06-01",{"name":5,"class":6},2]